

[¹²⁵I]-INSULIN-LIKE GROWTH FACTOR-1 (HUMAN, RECOMBINANT)

[¹²⁵I]-IGF-1

Product Number: NEX241

LOT SPECIFIC INFORMATION

CALCULATED AS OF: 15-Jul-2024

LOT NUMBER: FO82340

SPECIFIC ACTIVITY: 61.5 TBq/mmol
1663 Ci/mmol
7.9 MBq/μg
214 μCi/μg

UNBOUND IODIDE: < 5%

MOLECULAR WEIGHT 7773

Package Size Information

Package Size as of 23-Aug-2024
185 kBq 5 μCi
925 kBq 25 μCi

PACKAGING: [¹²⁵I]-IGF-1 is lyophilized from a solution containing 0.05M sodium phosphate, 1M glycine, 0.2M NaCl, and 0.25% BSA at pH 5.2. It is shipped ambient.

STABILITY AND STORAGE: The lyophilized [¹²⁵I]-IGF-1 should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 25 μCi/ml on calibration date, aliquot and store at -20°C or lower. Under these conditions the product is stable and usable for at least six weeks after fresh lot date.

SPECIFIC ACTIVITY: 210-360 μCi/μg (7.8-13.3 MBq/μg), 1630-2800 Ci/mmol (60-103 TBq/mmol) on fresh lot date as determined from ¹²⁵I incorporation into insulin-like growth factor-1. Equimolar protein and iodine implies 285 μCi/μg (10.5 MBq/μg). Specific activity decays with time.

RADIOCHEMICAL PURITY: Initially less than 5% unbound iodide as determined by thin layer chromatography

PREPARATIVE PROCEDURE: Insulin-like growth factor-1 is radioiodinated with no carrier added ¹²⁵I by a lactoperoxidase procedure¹ and purified by reversed phase HPLC. This method predominantly labels tyrosine residues.

AVAILABILITY: [¹²⁵I]-IGF-1 is routinely available from stock and is prepared fresh and packaged for shipment on the third Monday of each month. Please inquire for larger package sizes.

APPLICATIONS: Insulin-like growth factor-1 (an anabolic peptide hormone) stimulates growth, metabolism, and repair of damaged tissues. [¹²⁵I]-IGF-1 finds use in receptor binding, radioimmunoassay, and autoradiography.

HAZARD WARNING: This product contains a chemical(s) known to the state of California to cause cancer.
NEX241-R-REV01

This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, skin and respiratory tract. It is toxic.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

1. Morrison, M., Bayse, G. S., Webster, R. G., *Immunochemistry* 8, 289-297 (1971).

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations: Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA

(800) 762-4000
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright ©2023, Revvity, Inc. All rights reserved.